Copyright © 1993 by the European Society of Cardiology.
© 1993 The European Society of Cardiology
Ventricular remodelling: consequences and therapy
Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute Detroit, Michigan, U.S.A.
Correspondence: Goldstein, MD, Division Head, Cardiovasular Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202, U.S.A.
The mammalian left ventricle can change its size and shape in response to a variety of stimuli including loss of tissue and external work. These changes in size and shape, defined as remodelling, are the sum total of a number of processes that involve the myocyte and the interstitial fibrous structures which provide the matrix in which the myocyte functions. The adapted mechanisms which occur are affected by humoral and cellular phenomena and can be modified by pharmacological agents. This paper reviews the remodelling process that occurs in myocardial infarction and heart failure and the effect of various pharmacological agents on this remodelling process.
Key Words: Myocardial infarction heart failure ventricular function angiotensin converting enzyme inhibitors
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. S. Rubino, F. Onorati, G. Santarpino, E. Pasceri, G. Santarpia, L. Cristodoro, G. F. Serraino, and A. Renzulli Neurohormonal and echocardiographic results after CorCap and mitral annuloplasty for dilated cardiomyopathy. Ann. Thorac. Surg., September 1, 2009; 88(3): 719 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Taramasso, M. De Bonis, E. Lapenna, A. Verzini, G. La Canna, A. Grimaldi, and O. Alfieri Reverse Remodeling Effect of the CorCap Despite the Presence of Severe Mitral Regurgitation. Ann. Thorac. Surg., March 1, 2009; 87(3): e23 - e24. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Stassen, R. P. H. Derks, C. G. M. Kallenberg, and C. A. Stegeman Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors Rheumatology, April 1, 2008; 47(4): 530 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF] |
||||
![]() |
K. D Freigang, A. Bauer, R. Becker, J. C Senges, P. Kraft, J. Brachmann, W. Kubler, and W. Schoels Differential effects of d-sotalol on normal and infarcted myocardium: an experimental study using epicardial mapping Cardiovasc Res, July 1, 1997; 35(1): 52 - 59. [Abstract] [Full Text] [PDF] |
||||



